MiniMed has started its wear study for a tubeless pump, MiniMed Fit, designed to evaluate the adhesive components of the device across different wear locations over both a 5-day and 7-day period. The study supports development of what is expected to become MiniMed’s first commercialized patch pump.
MiniMed Fit is expected to feature a 300-unit reservoir and a 7-day wear time using MiniMed’s Extended Infusion Set technology. This capacity would be a first for a tubeless pump with 50% more insulin than today’s Omnipod 5 and Tandem’s upcoming tubeless Mobi.
The study is open to adults 18 and older with type 1 or type 2 diabetes and is being conducted at four U.S. locations: across California, New York, and Washington. It began in February and is expected to complete in May.
A study participant told us she received two prototypes—one placed on the lower back and the other on her arm. Both are identical in size, shape, and weight. There is no cannula and no insulin within these units. These trials are purely adhesive and wear testing.
MiniMed Fit wear study sample shown in two placement locations: on the back of the arm (left) and the lower back (right) to evaluate adhesive and wear. (Source: Study participant)
Last year, MiniMed sent out a survey asking users which color they preferred for the device, a small but telling sign of how much community input is shaping the product.
Beyond the Fit, MiniMed has a broader pipeline taking shape. It’s next-gen tubed pump, the MiniMed Flex is releasing this year. It’s half the size of the MiniMed 780G, screenless, and controlled through a smartphone. It will work with the Simplera Sync and Instinct CGMs, which suggests those sensors may eventually be compatible with the MiniMed Fit as well, a device we previously dove into in an All Access piece.
Further down the pipeline is a fully closed-loop algorithm, Vivera, that uses machine learning to study each user's glucose patterns and daily habits, automatically adjusting insulin dosing in real time without requiring routine meal boluses.
The tubeless pump space is getting heated—Tandem is working on tubeless Mobi, Beta Bionics working on its tubeless Mint pump, Omnipod developing a next-gen Omnipod 6, and now MiniMed is joining the lineup.
Our founder, Justin Eastzer, will be writing a deeper analysis of the MiniMed Fit for All Access members, coming soon. For now, let us know what you think of the MiniMed Fit in the comments below and let us know what questions you have.
Want more?
For the latest diabetes tech, join our free newsletter.
If you like our content and want more, join Diabetech All Access—unlocking exclusive Live Q&As, giveaways, stories and industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving.
Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.